Modified-Release Huperzine Compositions for Controlled Serum Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immediate release pharmaceutical compositions of huperzine A cause dose-related adverse events such as nausea and vomiting due to rapid serum exposure, necessitating frequent dosing and limiting therapeutic efficacy in neurological disorders and seizure disorders.
Innovation Solution
Modified release pharmaceutical compositions comprising a sugar sphere core, a huperzine layer, and a plasticized ethyl cellulose polymer layer, designed to achieve optimal plasma exposure and reduce adverse events by controlling serum levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release pharmaceutical compositions of huperzine A are used, then rapid serum exposure is achieved, but dose-related adverse events such as nausea and vomiting occur
Solution Approach 1:
The patent segments the huperzine A delivery system into multiple layers: a sugar sphere core, a huperzine layer, and a plasticized ethyl cellulose polymer layer. This segmentation allows controlled release of huperzine A, preventing rapid serum exposure and reducing adverse events while maintaining therapeutic efficacy.
Solution Approach 2:
The patent applies preliminary action by pre-coating the huperzine layer with a plasticized ethyl cellulose polymer layer before administration. This pre-formed coating structure ensures controlled release kinetics from the outset, preventing the rapid serum exposure that causes nausea and vomiting.
2Reliability
If immediate release pharmaceutical compositions of huperzine A are used, then therapeutic efficacy is achieved, but frequent dosing (4 to 6 times daily) is required
Solution Approach 1:
The patent implements continuity of useful action through the modified release formulation that maintains therapeutic levels of huperzine A in the serum over an extended period. The controlled release from the multi-layer structure ensures continuous therapeutic action, reducing dosing frequency from 4-6 times daily to twice daily while maintaining efficacy.
Solution Approach 2:
The patent applies dynamics by creating a time-dependent release profile where the plasticized ethyl cellulose polymer layer controls the rate of huperzine A release. This dynamic release mechanism adapts to maintain therapeutic levels over time, allowing less frequent dosing while preserving therapeutic efficacy.
3Reliability
If higher doses of huperzine A are administered to achieve efficacy in seizure disorders, then therapeutic threshold is reached, but serious adverse events increase
Solution Approach 1:
The patent changes the release rate parameter through the plasticized ethyl cellulose polymer coating, allowing higher total doses of huperzine A to be administered while controlling the release rate. This prevents peak serum concentrations that cause adverse events while maintaining therapeutic thresholds through sustained release.
Solution Approach 2:
The patent applies local quality by creating different functional zones within the pharmaceutical composition: the sugar sphere core provides structural support, the huperzine layer contains the active ingredient, and the plasticized ethyl cellulose polymer layer provides controlled release functionality. This localized functional differentiation enables higher doses with reduced adverse events.
Data Source
AI summary
The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and/or seizure disorders with the modified release compositions is also described.